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The incidence of end stage kidney disease is rising annually and it is now a global public health problem.
Current treatment options are dialysis or renal transplantation, which apart from their signiﬁcant
drawbacks in terms of increased morbidity and mortality, are placing an increasing economic burden on
society. Cell-based Regenerative Medicine Therapies (RMTs) have shown great promise in rodent models
of kidney disease, but clinical translation is hampered due to the lack of adequate safety and efﬁcacy
data. Furthermore, the mechanisms whereby the cell-based RMTs ameliorate injury are ill-deﬁned. For
instance, it is not always clear if the cells directly replace damaged renal tissue, or whether paracrine
effects are more important. Knowledge of the mechanisms responsible for the beneﬁcial effects of cell
therapies is crucial because it could lead to the development of safer and more effective RMTs in the
future. To address these questions, novel in vivo imaging strategies are needed to monitor the biodis-
tribution of cell-based RMTs and evaluate their beneﬁcial effects on host tissues and organs, as well as
any potential adverse effects. In this review we will discuss how state-of-the-art imaging modalities,
including bioluminescence, magnetic resonance, nuclear imaging, ultrasound and an emerging imaging
technology called multispectral optoacoustic tomography, can be used in combination with various
imaging probes to track the fate and biodistribution of cell-based RMTs in rodent models of kidney
disease, and evaluate their effect on renal function.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Cell-based regenerative medicine therapies (RMTs) are show-
ing great promise in rodent models of kidney disease (Bussolati
and Camussi, 2015; Murray and Woolf, 2014) but clinical transla-
tion of these novel therapies is currently hampered because ac-
curate safety and efﬁcacy data from the rodent studies are lacking.
These data are essential for determining the risk:beneﬁt ratio of
the RMTs in order to judge whether they would be appropriate for
use in man. A difﬁculty in assessing cell-based RMTs is that the
standard ‘absorption, distribution, metabolism and excretion’
(ADME) and pharmacokinetic (PK) testing that are used to assess
the disposition of pharmacological compounds are not directlyr B.V. This is an open access article
al Medicine, University of Li-
l L69 3GE, UK.applicable. This is mainly because, unlike pharmacological com-
pounds, cellular therapeutics can persist and even proliferate in
the recipient over the long-term, and also have the potential to
migrate to other tissues where they could cause adverse effects
(Heslop et al., 2015). Nevertheless, the general scientiﬁc principles
in the ﬁelds of pharmacology and toxicology should be considered
and applied where possible. The application of these principles is
facilitated by recent progress in the ﬁeld of in vivo imaging, which
is making it possible to visualise administered stem cells, track
their fate and ‘see’ the effects they have on host tissues and organs
(James and Gambhir, 2012; Meleshina et al., 2015; Wang and Yan,
2008), thus enabling the behaviour of administered cells to be
evaluated with a degree of accuracy that until now, has only been
possible for drugs. For instance, using the appropriate imaging
agent/imaging modality combination, it is possible to determine
how an administered cell population is distributed within each
body compartment, thus deﬁning the maximum tissue distribu-
tion (equivalent to ‘Cmax’ for administered drugs). Then byunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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deﬁne the complete spatiotemporal proﬁle of distribution
(equivalent to ‘pharmacokinetics’ (PK) for administered drugs) and
the rate of accumulation and elimination from target and non-
target tissues. Simultaneously, it is also possible to monitor the
biological effects on host tissues and organs, thus deﬁning the
complete spatiotemporal proﬁle of responses (equivalent to
‘pharmacodynamics’ (PD) for administered drugs). By co-register-
ing and correlating the kinetics and dynamics, it should be pos-
sible to deﬁne the efﬁcacy and safety for each cell therapy. In this
review, we will discuss how in vivo imaging technologies can be
used to evaluate cell-based RMTs in rodent models of kidney
disease, with particular focus on the biodistribution of cell-based
RMTs and their effect on renal function.2. Rodent models of kidney disease
Most studies investigating the potential of cell-based RMTs to
treat kidney disease have used rodent models of ischaemia re-
perfusion injury (IRI) (Donizetti-Oliveira et al., 2012; Feng et al.,
2016) or various drug-induced injury models, such as cisplatin,
adriamycin, aristolochic acid (Bruno et al., 2012; Li et al., 2012; Qi
and Wu, 2013; Ronconi et al., 2009) and the glycerol model of
induced rhabdomyolysis (Angelotti et al., 2012; Geng et al., 2014).
All of these models are clinically relevant. For instance, IRI, which
has been proposed to be the optimal model for evaluating cell-
based RMTs (Wang et al., 2012), represents the type of tubular
injury incurred by renal allografts during transplantation (Asder-
akis et al., 2001), and by the kidneys of patients undergoing car-
diopulmonary bypass surgery (Okusa et al., 2009). Clinical trials
have already been undertaken to assess the potential of me-
senchymal stem/stromal cells (MSCs) to ameliorate kidney disease
in cardiac surgery patients, with both positive and negative out-
comes being reported (NCT00733876; NCT01602328)(Gooch and
Westenfelder, 2016). A clinical trial is also currently underway to
establish the safety and feasibility of administering MSCs to cancer
patients receiving cisplatin (NCT01275612), an anti-cancer drug
that causes acute tubular injury, which in 20% of patients, pro-
gresses to chronic kidney disease (Inai et al., 2013). Likewise, the
safety and efﬁcacy of bone marrow-derived mononuclear cells are
being assessed in patients with focal segmental glomerulosclerosis
(NCT02693366), a disease that resembles adriamycin-induced
nephropathy in rodents (Scarfe et al., 2015). Cell-based therapies
for treating aristolochic acid and rhabdomyolysis-induced ne-
phropathy have only been tested in rodent models so far, but both
models are good representations of the tubulo-interstitial injury
that can occur in human patients following ingestion of aris-
tolochic acid (Yang et al., 2014) or crush injury (Gibney et al.,
2014), respectively.
A common problem with all rodent kidney injury models is
that the extent of injury incurred can vary considerably between
individuals within the same cohort, making it difﬁcult to accu-
rately assess the efﬁcacy of the cell therapies. Some studies ad-
dress this by using large numbers of animals in the treatment and
control groups, and culling animals at various time points (Ange-
lotti et al., 2012; Ronconi et al., 2009). However, an alternative
approach is to use methodologies that enable the same animal to
be evaluated over time, so that the extent of injury and therapeutic
response can be monitored in each individual animal. The key
advantage of undertaking such longitudinal assessments is that
correlated data are generated, thus increasing the power of the
statistical tests, which in compliance with the principles of ‘Re-
placement, Reﬁnement and Reduction’ (the ‘3Rs’), enables the
number of animals in these type of experiments to be reduced.3. Cell-based regenerative medicine therapies
The most common cell types used as RMTs include MSCs from
bone marrow (Qi and Wu, 2013) and adipose tissue (Donizetti-
Oliveira et al., 2012), kidney-derived progenitor cells (Ronconi
et al., 2009), renal progenitors derived from embryonic stem cells
or induced pluripotent stem cells (iPSCs) (Toyohara et al., 2015), or
heterogeneous populations such as adipose-derived regenerative
cells (Feng et al., 2010) or bone marrow-derived mononuclear cells
(Semedo et al., 2010). MSCs, adipose-derived regenerative cells
and bone marrow-derived mononuclear cells ameliorate renal
injury via paracrine factors, whereas kidney-derived progenitor
cells have been reported to engraft in the kidney and generate
specialised renal cells (Angelotti et al., 2012; Bussolati et al., 2005;
Ronconi et al., 2009). iPSC-derived renal progenitors can also en-
graft in the kidney and generate renal cells (Imberti et al., 2015;
Toyohara et al., 2015), though their therapeutic effects appear to
be mediated by paracrine mechanisms (Toyohara et al., 2015). As
an alternative to administering cells, several studies have in-
vestigated the therapeutic potential of cell-derived extracellular
vesicles, which in many cases, have been shown to be as efﬁca-
cious as the cells themselves (Bruno et al., 2009). It is anticipated
that extracellular vesicles would be less hazardous than cells as
they would not form tumours and would present a low risk of
forming emboli. As we will discuss in Section 5, it is crucial to
monitor the in vivo biodistribution of cellular therapeutics in order
to assess their safety, efﬁcacy and mechanisms of action. There are
two broad methods for labelling cells so that they can be tracked
following their administration:introducing a genetic reporter, or
labelling the cells with a nanoprobe or small molecules, such as
near infrared (NIR) dyes or ﬂuorescent proteins. For adipose-de-
rived regenerative cells and bone marrow-derived mononuclear
cells, which are heterogeneous populations of autologous cells that
are used at the point-of-care, it is not possible to introduce genetic
reporters, because this would require culturing the cells in vitro, a
process which would be expected to alter their composition and
phenotype. MSCs, iPSCs and kidney-derived progenitor cells on the
other hand, are routinely expanded in vitro, and so for these cell
types, there is the opportunity to introduce reporters. The bio-
distribution of extracellular vesicles can be monitored using both
genetic reporters and NIR dyes (Grange et al., 2014b; Lai et al.,
2014).4. Imaging agents and technologies
4.1. Imaging agents for cell tracking
Genetic reporters are excellent tools for tracking cell fate and
biodistribution in small animals. When expressed under the con-
trol of a constitutive promoter, reporter genes can be used for
long-term biodistribution analysis, as the signal is not depleted
when the cells proliferate. Constitutively expressed reporters also
indicate whether the cells are viable, because expression is rapidly
lost if the cells die. When expressed under the control of a cell-
type speciﬁc promoter, reporters can be used to monitor cell fate
and/or function by indicating the differentiation status of ad-
ministered cells. The most commonly used reporter for cell
tracking studies is ﬁreﬂy luciferase, an enzyme that emits light in
the presence of D-luciferin, oxygen and ATP and can be detected
using bioluminescence imaging. Other luciferases include the sea
pansy (Renilla reniformis) and marine cope pod luciferases (Gaussia
princeps), but compared to ﬁreﬂy luciferase, the Renilla is less in-
tense, and the Gaussia has a very short emission half-life (James
and Gambhir, 2012). In addition to bioluminescence imaging, ge-
netic reporters can also be used for imaging with other modalities;
Fig. 1. Radiance in the abdominal region of mice that received an intra-cardiac injection of luciferaseþ cells does not increase linearly. Mouse kidney-derived stem cells were
administered into the left cardiac ventricle in the range 1105 to 6105 and imaged immediately using BLI (IVIS Spectrum; Perkin Elmer). A region of interest (ROI) was
drawn in the same position on each animal as shown in (A), and the total Flux recorded in (B).
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ﬂuorescence (Lu et al., 2013) and photoacoustic imaging (Jathoul
et al., 2015), and cells expressing nuclear imaging reporters, such
as the human norepinephrine transporter, can be imaged with
single photon emission computed tomography (SPECT) following
administration of an appropriate substrate (e.g., 123I-MIBG; meta-
iodo-benzylguanine) (Moroz et al., 2007). There has also been
some interest in using reporter genes for magnetic resonance
imaging (MRI) (Velde et al., 2013), but the low sensitivity of MRI
reporters means they have limited use in cell tracking applications
(Pereira et al., 2016a, 2015, 2016b).
In addition to genetic reporters, nanoparticles and small mo-
lecules such as NIR dyes are also useful tools for tracking the
biodistribution of administered cells (Taylor et al., 2012). Unlike
the reporter genes, they cannot be used to monitor cell fate, and
due to them being depleted by 50% with each cell division, they
are not suitable for tracking proliferating cells in the long-term.
Furthermore, if the labelled cell dies, they can be taken up by host
cells, leading to false positive results (Taylor et al., 2012). However,
a key advantage of these non-genetically encoded imaging probes
is that in most cases, very high labelling efﬁciencies can be
achieved (typically over 95%) following relatively short incubation
times (4–24 h) (Taylor et al., 2014). Moreover, with the exception
of the luciferases, much higher signal intensities can be obtained
than with genetic reporters, making it possible to detect fewer
numbers of cells. There are a wide range of different types of non-
genetically encoded imaging probes, enabling cells to be tracked
with all the major imaging modalities. For instance, super-
paramagnetic iron oxide nanoparticles (Taylor et al., 2012) and
ﬂuorine (19F)-based imaging agents (Tirotta et al., 2014) are used
for MRI; gold nanorods and NIR dyes for photoacoustic imaging;
NIR dyes for ﬂuorescence imaging; persistent luminescent parti-
cles for bioluminescence imaging (Maldiney et al., 2014); techne-
tium (99mTc) for SPECT; 18F-ﬂuorodeoxyglucose (18F-FDG) for po-
sitron emission tomography (PET) (Rosado-de-Castro et al., 2014);
and perﬂuorocarbon nanoparticles for ultrasound imaging (Win-
ter, 2014).
4.2. Imaging technologies for tracking cells and monitoring their
effects on host tissues
The following imaging technologies can be used for cell track-
ing and assessing the effects of the cells on host tissues in small
animals: MRI, nuclear imaging (i.e., SPECT and PET), ultrasound,ﬂuorescence, bioluminescence and photoacoustic imaging. How-
ever, all of these modalities have some limitations (James and
Gambhir, 2012). For instance, MRI offers excellent spatial resolu-
tion, but temporal resolution is poor, so while organ-focussed
imaging is possible, performing whole body scans is not really
feasible. Nuclear imaging techniques permit whole body scanning
and generate quantitative data, but suffer from poor spatial re-
solution, and perhaps more importantly, require animals to be
exposed to ionising radiation, which is particularly problematic for
longitudinal studies that necessitate repeated scanning. Ultra-
sound imaging is safe, but mainly gives structural, rather than
molecular information, though when used in combination with
microbubble contrast agents, it can be very useful for monitoring
renal perfusion (Mahoney et al., 2014). Fluorescence imaging is
also safe, but sensitivity is poor and there is signiﬁcant signal at-
tenuation with increasing depth, so that 100,000 cells emitting
NIR ﬂuorescence would be required in an internal organ such as
the kidney in order to generate a detectable signal. Biolumines-
cence imaging is safe and has much greater sensitivity than MRI
and ﬂuorescence, allowing fewer than 100 cells to be detected, but
because the strength of the emitted signal is affected by various
parameters, including tissue depth and substrate availability (lu-
ciferin in the case of ﬁreﬂy luciferase), it can be difﬁcult to acquire
reliable quantitative data in some applications (Fig. 1). An emer-
ging imaging technology known as photoacoustic imaging over-
comes many of the limitations of the aforementioned modalities.
For instance, it has excellent sensitivity, allowing small numbers of
cells to be detected; spatial and temporal resolution are both very
good, permitting rapid whole body scanning of small rodents; it
can generate quantitative data; it is completely safe, allowing re-
peated scanning; and for small animals such as mice, a particular
type of photoacoustic scanner known as ‘multispectral optoa-
coustic tomography’ (‘MSOT’, built by iThera Medical Ltd) permits
the entire depth of a mouse to be imaged without signal at-
tenuation (Taruttis and Ntziachristos, 2015). However, a draw-back
with MSOT (and all other photoacoustic scanners) is that visuali-
sation of the lungs is not possible due to the presence of air in this
organ. This is an important issue for cell tracking because it is
known that most cell types tend to become trapped in the lungs
following intravenous administration (Fischer et al., 2009; Tögel
et al., 2008) and Fig. 2.
Although no single imaging technology/imaging agent is cap-
able of providing the breadth of information required, by using
multimodal strategies that combine different imaging
Fig. 2. Whole-body biodistribution of luciferaseþ cells using 3D diffuse light imaging tomography. Human kidney-derived cells expressing luciferase were administered
either intravenously or into the left cardiac ventricle of healthy mice and imaged immediately using a bioluminescence imager (IVIS Spectrum, Perkin Elmer). Following IV
administration, cells are located in the lungs, and following intra-cardiac administration, some cells are located in the kidneys.
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of administered cells while simultaneously evaluating the effects
on the tissues the cells populate. For instance, the easiest and most
useful strategy for monitoring the whole-body biodistribution of
cells in small animals is to introduce the ﬁreﬂy luciferase reporter
and undertake bioluminescence imaging. However, because the
spatial resolution of bioluminescence imaging is low and only a
planar image is generated, it is difﬁcult to pinpoint the exact lo-
cation of the cells on the z-axis. Although locating the cells on the
z-plane can be partially addressed by using 3D diffuse light ima-
ging tomography (Fig. 2), bioluminescence imaging does not allow
the intra-renal biodistribution of the cells to be monitored. How-
ever, this could be addressed by labelling the luciferaseþ cells with
either superparamagnetic iron oxide nanoparticles or gold na-
norods, and then undertaking bioluminescence imaging followed
immediately by MRI or MSOT, respectively.5. Biodistribution of RMTs in kidney disease models
5.1. Safety, efﬁcacy and mechanisms of action
To assess the safety of cell-based RMTs, knowledge of the bio-
distribution of the cells is required so that any potential adverse
effects on the tissues the cells populate can be monitored, the
most common potential adverse effects being embolism, in-
ﬂammation, ﬁbrosis, immunogenicity, mal-differentiation and tu-
mourigenesis (Heslop et al., 2015). The risk of any particular ad-
verse effect is dependent on the cell type. Larger cell types are
more likely to be entrapped in capillary beds and thus pose an
increased risk of emboli formation (Fischer et al., 2009), whereas
pluripotent cells have a greater propensity to form tumours. Par-
ticular care is needed with MSCs, which in some environments,
can readily differentiate to form osteoblasts, chondrocytes and/or
adipocytes, as shown in a previous study where MSCs adminis-
tered in a rat IRI model generated adipocytes within the glomeruli,
impairing renal function in the longer term (Kunter et al., 2007).
Biodistribution studies are also necessary to assess the efﬁcacy of
cell therapies; for instance, it is important to know what propor-
tion of the administered cell population reaches the kidneys, and
for how long they persist, so that the relationship between efﬁcacy
and the intra-renal distribution of the cells can be determined.This information can give valuable insight into the mechanisms of
action of the cells, as illustrated by a recent study by Geng et al.
(Geng et al., 2014) which showed that MSCs can ameliorate renal
injury in a mouse rhabdomyolysis model despite them not en-
grafting in the kidney. Follow-on experiments suggested that the
MSCs reduced kidney injury in this case by inducing endogenous
macrophages to adopt an M2-like (i.e., ‘anti-inﬂammatory)
phenotype.
5.2. Renal engraftment and the route of administration
Intravenous (i.v.) administration is the most commonly used
route for administering cells in rodent models of kidney injury.
Although it is well-documented that most cell types, including
MSCs, become entrapped in the pulmonary capillaries following i.
v. administration (Fischer et al., 2009), some reports suggest that
MSCs (Morigi et al., 2010) and kidney-derived progenitor cells
(Ronconi et al., 2009) can bypass the pulmonary circulation and
engraft in the kidney. It is important to note, however, that studies
reporting renal engraft of cells following i.v. administration typi-
cally use the lipophilic dye, PKH26, to identify cells in histological
sections of renal tissue, rather than using in vivo imaging ap-
proaches. The problem with lipophilic dyes is that they are readily
transferred to host cells, leading to false positive results (Agrawal
et al., 2014; Lassailly et al., 2010; Progatzky et al., 2013). This
problem is compounded by the fact that renal tissue emits high
levels of autoﬂuorescence, with levels being increased even fur-
ther following injury (Sun et al., 2011). Hence, there is a risk that
some of the patchy ﬂuorescence that appears in damaged renal
tissue could be mistaken for cells labelled with PKH26 or other
ﬂuorescent markers. Nevertheless, there are some reports that do
appear to show the presence of small numbers of cells in the
kidney following i.v. administration (Grange et al., 2014a). An ex-
planation for this could be that certain nephrotoxic agents (e.g.,
glycerol-induced rhabdomyolysis) also cause acute lung injury,
with the resulting hypoxia (Rodrigo et al., 2006) potentially lead-
ing to the recruitment of intrapulmonary arteriovenous anasto-
moses (IPAVAs) (Bates et al., 2012). IPAVAs are large diameter
vessels in the lung that directly connect the arterial and venous
networks, thus bypassing the pulmonary capillaries (Lovering
et al., 2010). Interestingly, if 106 15 mm diameter ﬂuorescent mi-
crospheres (approximately the same diameter as mouse MSCs) are
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ditions, no beads are observed in the kidneys, whereas under
hypoxic conditions, approximately 103 beads are detected (Bates
et al., 2012). Each kidney receives 10% of the cardiac output, so if
106 beads were injected into the left cardiac ventricle, it would be
expected that 105 would reach the kidneys. The fact that 103 beads
are detected following i.v. administration in hypoxic rats shows
that under these conditions, 1% of injected beads can reach the
kidneys. By extrapolation, this study suggests that if cells are ad-
ministered i.v. into hypoxic rodents, it is possible that 1% could
engraft in the kidneys. This could explain why in some studies,
cells can be observed in the kidneys following i.v. administration,
but not in others. However, the small numbers of engrafting cells
strongly suggests that the observed therapeutic effects are likely to
be mediated by paracrine factors released from the remaining
90% of the cell population that is entrapped within the lungs.
To circumvent the ‘problem’ of lung entrapment, cells can be
delivered into the kidney by administering then on the arterial
side of the circulation. In rats, cells can be administered via the
renal artery, whereas in mice, the cells need to be administered via
the suprarenal aorta (Tögel et al., 2008) or left cardiac ventricle
(Fig. 2), due to the renal artery being too small. Following ad-
ministration of luciferaseþ MSCs into the suprarenal aorta, biolu-
minescence imaging showed that MSCs were initially present in
the kidneys, but by 24 h, were mainly located in the lung (Tögel
et al., 2008). Similar results were obtained following administra-
tion of human MSCs into the left cardiac ventricle, where histo-
logical analysis showed that cells were observed in the kidneys
shortly after being injected, but by 4 weeks, were barely
detectable (Bentzon et al., 2005). Likewise, following administra-
tion of adipose-derived regenerative cells into the renal artery of
rats, cells were initially present within the glomerular capillaries
but had almost disappeared by 72 h (Feng et al., 2010). Of note, a
study by Zhuo et al. (Zhuo et al., 2013) showed that it luciferaseþ
MSCs were injected into the right renal artery of rats subjected to
IRI, bioluminescence was mainly observed in the lung. This is an
interesting observation because it suggests that even when cells
are injected into the renal artery, the majority exit via the renal
vein and become entrapped in the lung. Analysis of renal function
and histology in this rat IRI model showed that the therapeutic
effects of the MSCs were similar, irrespective of whether they were
administered i.v. or via the renal artery, which in light of the
biodistribution data, is perhaps not too surprising (Zhuo et al.,
2013). Consistent with these ﬁndings, a recent meta-analysis
shows that cell-based RMTs administered either i.v. or via the
renal artery are similarly efﬁcacious in rodent models of chronic
kidney disease (Papazova et al., 2015). Moreover, the extent of the
therapeutic response appears to be independent of cell dose and
the number of administrations.
Cell therapies can also be introduced into the kidney by direct
injection into the parenchyma (Harari-Steinberg et al., 2013;
Toyohara et al., 2015) or by injecting under the renal capsule
(Toyohara et al., 2015), though the invasive nature of these ad-
ministration routes means they would have little clinical utility.
Toyohara et al. showed that although iPSC-derived renal pro-
genitors could integrate into renal tubules following parenchymal
injection, the cells did not ameliorate injury in a mouse IRI model.
Conversely, following administration under the renal capsule, the
cells did not integrate into tubules but could promote renal re-
covery (Toyohara et al., 2015). These interesting results could
possibly be explained by the fact that the subcapsular region of the
kidney is a permissive environment that can support the growth of
various cell types, including pancreatic islets and pluripotent cells
(teratoma assays). Thus, the improved therapeutic efﬁcacy ob-
served following subcapsular administration might have simply
been due to the fact that the iPSC-derived renal progenitors couldsurvive for longer in this environment. In support of this, a more
recent study has shown that if MSCs are injected into the renal
parenchyma within a chitosan-based hydrogel that supports their
survival, improved therapeutic efﬁcacy is observed in a mouse
model of IRI (Feng et al., 2016).
5.3. Whole-body biodistribution of cell-based RMTs in rodent models
of kidney disease
A number of studies have shown that renal engraftment of cell-
based RMTs increases in some models of kidney injury (Tögel
et al., 2008; Grange et al., 2014b). For instance, intra-arterial ad-
ministration of MSCs in a mouse IRI model leads to a short-term
increase in the numbers of cells in the kidneys of injured mice
compared with sham-operated controls (Tögel et al., 2008). This
increased ‘homing’ could either be due to the injured renal tissue
secreting chemo-attractants, or could simply result from the MSCs
getting temporarily stuck in the glomerular capillaries because of
the decrease in capillary perfusion that typically occurs following
ischaemic injury (Jerome et al., 1994).
Monitoring the whole-body biodistribution of cell therapies is
particularly important in models where the nephrotoxic agent
damages non-renal tissue as well as the kidneys. This is because
cell-based RMTs can readily engraft in various types of injured
tissue, as shown in a study where MSCs injected into the aortic
arch proliferated in a region of the mouse hind limb that had been
damaged with radiation (Kean et al., 2013). Examples of such
models include glycerol-induced rhabdomyolysis, which causes
damage to the injected muscle and lungs, and adriamycin, which
damages the heart and bone marrow (To et al., 2003). Indeed,
intra-vital microscopy showed that MSCs labelled with a red
ﬂuorescent protein could be detected in the lung and muscle in a
mouse rhabdomyolysis model (Geng et al., 2014). Likewise, work
from our own laboratory shows that following administration of
luciferaseþ mouse kidney-derived stem cells (Fuente Mora et al.,
2012) in a mouse model of adriamycin-induced nephropathy, cells
engrafted in areas corresponding to the location of the heart and
femoral bone marrow, but not in the kidneys (Fig. 3).6. Monitoring the effect of RMTs on renal function
The glomerular ﬁltration rate (GFR) is the most accurate mea-
sure of renal excretory function, but obtaining the GFR requires
repeated blood and/or continuous urine sampling over a pro-
longed period (5–24 h), which is technically challenging in ro-
dents, particularly in mice, where blood is usually only taken fol-
lowing animal sacriﬁce via cardiac puncture. For this reason, an
‘estimated’ GFR based on levels of serum creatinine is typically
used. However, a problem with using serum creatinine measure-
ments is that between 35% and 50% of creatinine is excreted via
tubular secretion in rodents rather than glomerular ﬁltration
(Eisner et al., 2010), making it a poor predictor of GFR. This pro-
blem can be addressed by using a novel electronic device that can
give an accurate indication of GFR in rodents by measuring the
half-life of intravenously administered FITC-sinistrin (Schock-
Kusch et al., 2011), a molecule that is exclusively ﬁltered by the
glomeruli. This device has recently been used to monitor changes
in GFR in a mouse adriamycin model, where the measurements
showed a strong positive correlation with the extent of glomerular
histological damage (Scarfe et al., 2015). However, while the
transcutaneous device allows longitudinal GFR measurements to
be obtained, it does not provide any anatomical information, and
cannot be applied to models where only one kidney is injured, as
the device measures the global GFR, and does not give a mea-
surement for each individual kidney. Whole animal imaging
Fig. 3. Whole-body biodistribution of luciferaseþ mouse kidney-derived stem cells using bioluminescence imaging. Cells were administered into the left cardiac ventricle on
the 2nd day following IV injection of adriamycin or saline (healthy control) and mice were imaged immediately or 2 weeks later using a bioluminescence imager (IVIS
Spectrum, Perkin Elmer). Mice that received adriamycin showed engraftment of cells in regions corresponding to the heart and femoral bone marrow, but not in the kidneys.
No cells were detected in control mice at this time point.
Fig. 4. T2-weighted MR scan of the kidneys of a healthy mouse imaged in vivo
using a Bruker 9.4 T MR scanner.
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itudinal studies required to monitor disease progression and
therapeutic responses in the same animals over time. This ap-
proach is far superior to sacriﬁcing animals at set time points and
undertaking histological analyses, because apart from reducing
animal numbers, the longitudinal data obtained offers the oppor-
tunity to observe patterns of change at an individual level, as well
as increasing the statistical power of the experiment. MRI, nuclear
imaging techniques (SPECT and PET) and ultrasound can all be
used to monitor the efﬁcacy of cell-based RMTs, but the multi-
plexing capability of MSOT offers unprecedented opportunities to
monitor various aspects of renal function simultaneously, and will
thus be discussed in more detail.
6.1. MRI, SPECT, PET and ultrasound
Of all the in vivo imaging modalities, MRI gives the highest
spatial resolution and is therefore the modality of choice for per-
forming anatomical imaging of the kidney (Fig. 4). As kidney dis-
ease progresses, morphological changes occur in the renal par-
enchyma, which can be monitored using 3D rendering to assess
organ volume changes (Zöllner et al., 2013), and with diffusion
weighted imaging to monitor changes in renal microarchitecture
(Ebrahimi et al., 2013). MRI can also be used to monitor various
aspects of renal function, such as renal perfusion and the GFR
(using dynamic contrast enhanced MRI), as demonstrated in rat
models of adriamycin-induced kidney injury and uninephrectomy,
respectively (Egger et al., 2015; Zöllner et al., 2013).
The nuclear imaging techniques, SPECT and PET, do not give anyanatomical information and thus require co-registration with MRI
or computed tomography (CT), but can be extremely useful for
assessing renal function (Durand et al., 2011). For instance, the
SPECT tracer, technetium-99 m-mercaptoacetyltriglycine (99mTc-
MAG3), is routinely used in the clinic to monitor tubular secretion,
and can also be applied to small rodents, as shown in a study
where this strategy was used to monitor renal function over time
in a mouse model of unilateral IRI (Herrler et al., 2012). SPECT can
also be used to monitor GFR by measuring the clearance of the
glomerular tracer, 99mTc- diethylenetriamine penta-acetate
(DTPA), which has been used to investigate the renoprotective
effects of oestrogen in a rat model of ureteric obstruction (Mao
et al., 2014). More recently, a novel PET tracer, 2-deoxy-2-18F-
ﬂuorodeoxysorbitol (18F-FDS) has been developed, which like
99mTc-DTPA, can be used to monitor GFR (Wakabayashi et al.,
2016). The advantage of PET over SPECT is that in the clinical
J. Sharkey et al. / European Journal of Pharmacology 790 (2016) 74–8280setting, it offers higher spatial and temporal resolution, enabling
more accurate quantitative data to be obtained.
Ultrasound is routinely performed in the clinic to assess renal
morphology, and by using Doppler ultrasound, it is possible to
monitor renal perfusion (To et al., 2003). The availability of small
animal ultrasound scanners now makes it possible to assess renal
morphology and function longitudinally in rodents. For instance,
by undertaking contrast enhanced ultrasound with microbubble
contrast agents, it is possible to monitor regional blood ﬂow
longitudinally in the mouse kidney (Sullivan et al., 2009). This
technique has been used to monitor renal microperfusion in a
mouse IRI model, and to assess the changes in perfusion that occur
in the outer medulla over time (Fischer et al., 2016).
6.2. MSOT
Multispectral optoacoustic tomography (MSOT) is a technique
which relies on the photoacoustic effect to facilitate the volumetric
and quantitative visualisation of tissues in vivo without the ne-
cessity for contrast agents. A laser is used to pulse light of multiple
wavelengths towards a target tissue or organ, permitting imaging
at high spatial resolution (150 mm) to a depth of 3 cm. This light
is absorbed by endogenous photo-absorbers within the target
tissue, which undergo thermoelastic expansion to generate sound
waves that are detected by acoustic detectors (Mandal et al., 2015).
A particular advantage of MSOT over other imaging modalities is
its multiplexing capability, which arises from the ability of the
scanner to distinguish different absorbance spectra, enabling
several molecular targets to be detected simultaneously. Oxyhae-
moglobin and deoxyhaemoglobin are particularly strong intrinsic
absorbers that can be readily distinguished by MSOT (Buehler
et al., 2010; Wang and Hu, 2012), and could thus provide valuableFig. 5. (A) MSOT images showing the cross-section of a healthy mouse prior to and post
represents the renal cortex and pelvis, respectively. The dye is present in the cortex at the
has cleared from the cortex. (B) Graph showing the accumulation and clearance of IRDye
color in this ﬁgure legend, the reader is referred to the web version of this article.)information on renal perfusion, vascularisation and oxygenation,
as has recently been undertaken with tumour tissue (Ermolayev
et al., 2016). MSOT not only allows the visualisation of endogenous
molecules, but also the simultaneous imaging of exogenous NIR
dyes, proteins and nanoparticles such as gold nanorods, which
absorb light in the NIR region of the spectrum (Deliolanis et al.,
2014). MSOT can acquire cross-sectional images of anaesthetised
small animals that can be taken in sequential steps to build a 3D
image of the target tissue or organ. Alternatively, one cross-sec-
tional plane can be acquired for the duration of the imaging ses-
sion to permit the fast dynamic scanning required for real-time
pharmacokinetic analyses. This can be utilised to analyse the ac-
cumulation and/or clearance of exogenous NIR tracers in different
regions of the kidney, enabling different aspects of renal function
to be monitored (Fig. 5). In a recently published study by Scarfe
et al. (Scarfe et al., 2015), MSOT was used to monitor renal function
longitudinally in a mouse adriamycin model. This was achieved by
measuring the clearance of IRDye 800 carboxylate, an NIR dye that
is rapidly and exclusively excreted by the kidneys (Taruttis et al.,
2012). The Scarfe study showed that the time between the mean
peak pixel intensity in the cortex and the pelvis (TMAX delay) was
signiﬁcantly greater in mice with adriamycin-induced nephro-
pathy than in healthy mice. Furthermore, the TMAX delay corre-
lated strongly with glomerular scarring, as determined by histo-
logical analysis. The multiplexing capability of MSOT means that if
the appropriate NIR tracers were available (i.e., tracers that were
either exclusively ﬁltered or secreted), it would be possible to
assess these two important aspects of renal function simulta-
neously. In conclusion, MSOT is a tool which has a range of ap-
plications for assessing RMTs in kidney disease models: due to its
high spatial resolution it can be used to assess renal morphology;
it can indicate the oxygenation status of the kidney; it can be usedadministration of IRDye800 carboxylate (20 nmol). Blue and red regions of interest
10 s time point, and by 1 min, starts to accumulate in the pelvis. By 10 min, the dye
800 carboxylate from the cortex and pelvis. (For interpretation of the references to
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cellular vesicles; and by monitoring the pharmacokinetics of ren-
ally excreted NIR dyes, it can accurately assess renal function.7. Concluding remarks
The development and application of in vivo imaging strategies
to accurately assess the safety, efﬁcacy and mechanisms of action
of cell-based RMTs will lead to a better understanding of their
potential hazards and therapeutic beneﬁts, thus underpinning the
safe introduction of these new therapies into the clinic. Indeed,
in vivo imaging approaches are already providing novel insights
into the mechanisms of action of RMTs in rodent models of kidney
disease, which is likely to lead to safer and more effective thera-
pies in the future. For instance, we now know that for the majority
of therapeutic cell-types, the regenerative effects on host renal
tissue are mediated by paracrine or endocrine factors. Therefore, if
these factors could be deﬁned, it could be possible to administer
them instead of the cells, thus bypassing some of the potential
hazards associated with cell administration. Although the focus of
this review has been on renal cell-based RMTs, it is worth noting
that in rodent models of various other diseases, including heart
disease (Malliaras and Marban, 2011) and spinal cord injury (De
Paul et al., 2015), there is increasing evidence that the therapeutic
effects are mediated by paracrine factors rather than by the cells
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